Therapeutic effects of pharmacologically induced hypothermia against traumatic brain injury in mice.

Abstract

Preclinical and clinical studies have shown therapeutic potential of mild-to-moderate hypothermia for treatments of stroke and traumatic brain injury (TBI). Physical cooling in humans, however, is usually slow, cumbersome, and necessitates sedation that prevents early application in clinical settings and causes several side effects. Our recent study showed that pharmacologically induced hypothermia (PIH) using a novel neurotensin receptor 1 (NTR1) agonist, HPI-201 (also known as ABS-201), is efficient and effective in inducing therapeutic hypothermia and protecting the brain from ischemic and hemorrhagic stroke in mice. The present investigation tested another second-generation NTR1 agonist, HPI-363, for its hypothermic and protective effect against TBI. Adult male mice were subjected to controlled cortical impact (CCI) (velocity=3 m/sec, depth=1.0 mm, contact time=150 msec) to the exposed cortex. Intraperitoneal administration of HPI-363 (0.3 mg/kg) reduced body temperature by 3-5°C within 30-60 min without triggering a shivering defensive reaction. An additional two injections sustained the hypothermic effect in conscious mice for up to 6 h. This PIH treatment was initiated 15, 60, or 120 min after the onset of TBI, and significantly reduced the contusion volume measured 3 days after TBI. HPI-363 attenuated caspase-3 activation, Bax expression, and TUNEL-positive cells in the pericontusion region. In blood-brain barrier assessments, HPI-363 ameliorated extravasation of Evans blue dye and immunoglobulin G, attenuated the MMP-9 expression, and decreased the number of microglia cells in the post-TBI brain. HPI-363 decreased the mRNA expression of tumor necrosis factor-α and interleukin-1β (IL-1β), but increased IL-6 and IL-10 levels. Compared with TBI control mice, HPI-363 treatments improved sensorimotor functional recovery after TBI. These findings suggest that the second generation NTR-1 agonists, such as HPI-363, are efficient hypothermic-inducing compounds that have a strong potential in the management of TBI.

• Authors: Jin Hwan Lee, Ling Wei, Xiaohuan Gu, Zheng Wei, Thomas A Dix, Shan Ping Yu
• Journal: Journal of neurotrauma (J Neurotrauma) Vol. 31 Issue 16 Pg. 1417-30 (Aug 15 2014) ISSN: 1557-9042 [Electronic] United States
• PMID: 24731132 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• HPI-363
• Oligopeptides
• Receptors, Neurotensin
• neurotensin type 1 receptor

Topics

• Animals
• Blotting, Western
• Brain Injuries (pathology)
• Disease Models, Animal
• Hypothermia, Induced (methods)
• Immunohistochemistry
• In Situ Nick-End Labeling
• Male
• Mice
• Mice, Inbred C57BL
• Oligopeptides (pharmacology)
• Real-Time Polymerase Chain Reaction
• Receptors, Neurotensin (agonists)